Weight Management
Genetics can indeed play a significant role in determining an individual's susceptibility to obesity and their response to weight management interventions. Numerous studies have shown that genetic factors contribute to a person's risk of obesity. Certain gene variants can predispose individuals to gain weight more easily than others in response to the same diet and exercise regimen. Genetic variations can affect metabolic rate and energy expenditure. Some people may have a naturally higher metabolic rate, meaning they burn more calories at rest, while others may have a slower metabolism, making it easier for them to gain weight. Genetics also influence how fat is stored and distributed in the body. Some individuals may have a genetic tendency to store fat predominantly in certain areas, such as the abdomen or hips, which can impact overall body weight and shape. Genetic factors can influence appetite regulation and satiety signals. Variations in genes related to hunger hormones like leptin and ghrelin can affect how full or satisfied a person feels after eating, potentially influencing their food intake and weight management efforts.
We now know that people are overweight because we live with food abundance and due to genetics, some people will need more food to feel fuller and food hunger signals return sooner. It is not a matter of “control” or “greed” because appetite is out of our conscious control and there is now medication available that improves appetite regulation and satiety signals.
GLP-1 (glucagon-like peptide-1) medications, also known as GLP-1 receptor agonists, are a class of drugs used in the treatment of type 2 diabetes and obesity. These medications mimic the action of the natural hormone GLP-1, which is released from the intestine in response to food intake. While GLP-1 primarily acts on the pancreas to stimulate insulin secretion and reduce glucagon release, it also has effects on the brain, particularly in areas involved in appetite regulation and satiety. They work on the brain by:
Appetite Regulation: GLP-1 receptors are found in several areas of the brain, including the hypothalamus, which plays a crucial role in appetite regulation. When GLP-1 binds to its receptors in the brain, it activates signaling pathways that reduce feelings of hunger and increase feelings of fullness or satiety. This can lead to decreased food intake and ultimately contribute to weight loss.
Reward Pathways: GLP-1 receptors are also present in brain regions associated with reward and motivation, such as the mesolimbic dopamine system. Activation of these receptors may modulate reward processing and reduce the rewarding properties of food, which could help individuals resist overeating or consuming high-calorie foods.
Gut-Brain Axis: GLP-1 released from the gut in response to food intake can signal to the brain via the gut-brain axis, a bidirectional communication pathway between the gastrointestinal tract and the central nervous system. By modulating this communication, GLP-1 medications can influence neuronal activity and neurotransmitter release in brain regions involved in appetite control and energy balance.
Gastric Emptying: GLP-1 medications can also slow gastric emptying, meaning food stays in the stomach longer before being passed into the small intestine. This delay in gastric emptying can prolong feelings of fullness and reduce the rate at which glucose is absorbed into the bloodstream after meals, which may help regulate appetite and improve glycemic control in individuals with diabetes.
If you would like to receive a free of charge consultation on whether you would be a good candidate for medication for weight loss, please start by completing this consultation form:
Or, make a booking for a video consultation to discuss in person: